Tag Archives: XGeva

January, 2018

June, 2017

October, 2016

December, 2015

  • 15 December

    Amgen Reacquires Rights to Three Drugs from GSK

    THOUSAND OAKS, Calif., Dec. 14, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia® (denosumab), XGEVA®(denosumab) and Vectibix® (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world. …